1 / 55

3. Method of inspection

3. Method of inspection. Requirements for the Method of Inspection We assume that k a is much larger than k el . That is, k a is at least five times greater than k el . This is the same requirement as for the Method of Residuals

ora-ramirez
Download Presentation

3. Method of inspection

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. 3. Method of inspection Requirements for the Method of Inspection • We assume that ka is much larger than kel. That is, ka is at least five times greater than kel. This is the same requirement as for the Method of Residuals • Assume that absorption is complete (i.e. greater than 95 % complete) at the time of the peak concentration.

  2. The Method • The first step is to estimate the time of the peak drug concentration by inspection. If we assume that the time of peak is approximately five times the absorption half-life: • tpeak = 5 * t1/2(absorption)

  3. Ka = (ln 2)/t1/2 (absorption) • Ka = 0.693/t1/2(absorption) • Ka = 0.693/ (tpeak/5) • Ka = 0.693*5 / (tpeak)

  4. Extent of absorption, F value the fraction of the dose which is absorbed is termed F Plotting Cp versus time allow the calculation of ka and kel, as in the methods described previously.

  5. From the intercept, one can calculate the term: • The total amount absorbed can be calculated as:

  6. The following data was collected after administration of an IV and oral dose to a subject. Calculate Cpo, Vd, and the bioavailability (F), as well as other kinetic parameters.

  7. IV data , Dose = 100 mg

  8. Thus the intercept value is 2.50 and the apparent volume of distribution is Dose/Cp0 = 100/2.5 = 40 L. From the slope kel can be estimated as 0.201 hr-1. The AUC (AUC = Dose/VdKel) from the IV data is 12.6 mg.hr.L-1.

  9. Oral Dose = 250 mg

  10. Semi-log Plot of Drug Concentration versus Time after an Oral dose

  11. The time of peak concentration is 1.5 hour, thus the t1/2 absorption might be estimated to be 0.3 hour: • and the absorption rate constant to be approximately 2.3 hr-1. • Ka = 0.693/t1/2 = 0.693/0.3 = 2.31 • The AUC from the oral data is 24.91 mg.hr.L-1 and thus the bioavailability might be estimated as • F = (24.68 x 100) / (250 x 12.6) = 0.78 t1/2 absorption = 1.5/5 = 0.3hr

  12. Excretion in Urine Scheme for drug excreted into urine, one compartment

  13. The rate of elimination from plasma is the same as the rate of appearance of drug into urine Dose = Amount in body + Amount excreted in urine = Vd * Cp + U

  14. t = t e-Kel*t/-Kel t = o Plot Types: a. Cumulative amount versus time • Rate of appearance of drug in urine = rate of drug elimination from plasma • dU/dt = Kel Vd Cp • Cp = Cpo e-kel*t • dU/dt = Kel Vd Cpo e-kel*t • Dose = Vd Cpo • dU/dt = Kel Dose e-kel*t • dU = Kel Dose e-kel*t .dt • Integration of e-kel*t =

  15. (e-Kel*t/-Kel) - (1/-Kel) • U = Kel Dose thenU = DOSE [1 – e -kel * t] Cumulative amount excreted into urine at time = t At t = 0; e -kel * t = 1 then U0= DOSE [1 - 1] = 0 At t = infinity ; e -kel * t = 0 then U = DOSE [1 - 0] = DOSE

  16. Plot of Cp versus Time and U versus Time

  17. b. Rate of excretion Taking the logarithms of both sides gives:- Thus by plotting ln (dU/dt) versus time should result in a straight line with a slope of - kel.

  18. The amount excreted is the product of the volume of urine voided and concentration of drug in the urine sample. Again, this is a rate measurement. Since we estimate dU/dt as U/t, an average rate of excretion over the collection interval, the t value used with this plot is the time at the midpoint of the collection interval

  19. Example: • Ampicillin almost 100% (actually closer to 90%) excreted unchanged into urine. • After giving an IV dose of 500 mg, urine is collected and assayed for drug content. Data collected is time interval versus amount (mg) excreted during the time interval. The cumulative amount excreted is readily calculated. The following table summarizes the results:

  20. The plot shows U rapidly increasing at first then leveling off to Ua where Ua = DOSE for this set of data. Notice that Ua/2 (250 mg) is excreted in about 1½ hours. Otherwise it is a fairly qualitative representation of the data. Plot of Cumulative Amount Excreted versus Time

  21. We can then calculate the rate of excretion during each time interval. Then the time point is the midpoint time. If we plot U/t versus t midpoint on semi-log graph paper we have the blue squares on the graph paper. As you can see this gives a straight line plot. • From the equation before we have:- • Intercept = ln (DOSE * kel) • Slope = - kel

  22. Plot of Rate of Excretion and A.R.E. versus Time

  23. kel = 0.440 hr - 1 (t1/2 = 1.58 hr) Consequently with this plot we can estimate kel and t1/2.

  24. C. Amount remaining to be excreted (A.R.E.) • There is a third method of plotting the data which is commonly used. That is the amount remaining to be excreted (A.R.E.) plot. The equation describing this plot can be derived from the differential equation.

  25. Since, DOSE = Amount in body + Amount eliminated Thus, DOSE = V * Cp + U = Ua Ua, total amount excreted Then Ua - U = V.Cp Ua - U = Ua.r.e (amount remaining to be extracted dU/dt = Kel Ua.r.e

  26. dU / Ua.r.e = Kel*dtIntegrating from t = 0 to t = t, and from U = Ua.r.e to U = Ua, gives: • ln Ua - ln Ua.r.e = Kel * t • OR • ln Ua.r.e = ln Ua - Kel * t

  27. Thus by plotting ln Ua.r.e versus time we should get a straight line with a slope of - kel. Since the term Ua.r.e is called the amount remaining to be excreted (A.R.E.), then if we subtract U from Ua at each time point we are calculating A.R.E. (Ua.r.e) or (Ua - U). These results are shown as red circles on the semi- log graph paper kel = 0.464 hr - 1

  28. Risk Assessment and Management

  29. Location of Risk Assessment

  30. Health risk assessment, or herein risk assessment (RA) for short, is the process by which the potential adverse health effects of human exposure to etiologic agents are characterized and assessed. Etiologic agents are agents that may modify the frequency or distribution of adverse health effects (also more commonly referred to as diseases) in a human community.

  31. IUPAC Definitions HAZARD vs. RISK hazard: inherent property of an agent capable of having adverse effects on something. risk: the probability of adverse effects caused under specified circumstances by an agent

  32. DOSE vs. CONCENTRATION dose: total amount of a substance administered to, taken, or absorbed by an organism concentration: quantity of a material or substance contained in unit quantity of a given medium or system

  33. adverseeffect: change in morphology, physiology, growth, development, or life span of an organism, which results in an impairment of functional capacity, an impairment of the capacity to compensate for additional stress, or an increase in susceptibility to other environmental influences

  34. exposure: Concentration, amount, or intensity of a particular agent that reaches a target system. dose-response relationship: link between the amount of an agent absorbed by a population and the change developed in that population in reaction to it

  35. Response versus effect The response may be expressed as the proportion of a population exposed to an agent that shows a specific reaction (dose – response relationship). It may also be used to signify the magnitude of an effect (severity) in one organism (or part of an organism); in that case, it is more specifically called "dose-effect relationship".

  36. SAFETY AND UNCERTAINTY safety: practical certainty that adverse effects will not be caused by an agent under defined circumstancesNote: It is a reciprocal of risk. safety factor: factor by which an observed or estimated toxic concentration or dose is divided to arrive at a criterion or standard that is considered safe

  37. ACCEPTABLE DAILY INTAKE (ADI) acceptable daily intake: maximum amount of a substance to which a subject may be exposed daily over the subject’s lifetime without appreciable health risk tolerable intake: estimate of the amount of a substance that can be ingested or absorbed over a specified period of time without appreciable health risk

  38. hazard assessment: process designed to determine factors contributing to the possible adverse effects of a substance to which a human population or an environmental compartment could be exposed. The process includes three steps: hazard identification, hazard characterization, and hazard evaluation. Note: Factors may include mechanisms of toxicity, dose-effect and dose-response relationships, variations in target susceptibility, etc

  39. hazard identification: the first stage in hazard assessment, consisting of the determination of substances of concern, the adverse effects they may have inherently on target systems under certain conditions of exposure, taking into account toxicity data

  40. hazard characterization: the second step in the process of hazard assessment, consisting in the qualitative and, wherever possible, quantitative description of the nature of the hazard associated with a biological, chemical, or physical agent, based on one or more elements, such as mechanisms of action involved, biological extrapolation, dose-response and dose-effect relationships, and their respective attendant uncertainties

  41. hazard evaluation: the third step in the process of hazard assessment aiming at the determination of the qualitative and quantitative relationship between exposure to a hazard under certain conditions, including attendant uncertainties and the resultant adverse effect

  42. risk assessment: process intended to calculate or estimate the risk for a given target system following exposure to a particular substance, taking into account the inherent characteristics of a substance of concern as well as the characteristics of the specific target system. The process includes four steps: hazard identification, dose-response assessment, exposure assessment, and risk characterization. It is also the first step in risk analysis

  43. hazard identification: the first stage in risk assessment, consisting of the determination of particular hazards a given target system may be exposed to, including attendant toxicity dataNote: Definition may vary depending on the context. Thus, here: the first stage in hazard assessment, consisting of the determination of substances of concern and the adverse effects they may inherently have on target systems under certain conditions of exposure, taking into account toxicity data.

  44. dose-response assessment: the second of four steps in risk assessment, consisting of the analysis of the relationship between the total amount of an agent absorbed by a group of organisms and the changes developed in the group in reaction to the agent, and inferences derived from such an analysis with respect to the entire population

  45. exposure assessment: a step in the process of risk assessment, consisting of a quantitative and qualitative analysis of the presence of an agent (including its derivatives) that may be present in a given environment and the inference of the possible consequences it may have for a given population of particular concern

More Related